2023ÄêµÄ¿ÆѧͻÆƽ±ºÍÒýÎĹð¹Ú½±¶¼ÊÚÓèÁËÔÚCAR-Tϸ°ûÁÆ·¨ÖÐ×÷Ϊ¿ª´´ÐÔÊÂÇéµÄ Carl June½ÌÊÚºÍMichel Sadelain½ÌÊÚ£¬£¬ £¬£¬£¬£¬ÕâÒ²ÈÃËûÃdzÉΪÈÈÃŵÄŵ½±ºòÑ¡ÈË¡£¡£
ÔÚ¼ÍÄî˹¡¿ÌØÁÕ°©Ö¢ÖÐÐÄÊÂÇéʱ´ú£¬£¬ £¬£¬£¬£¬Michel Sadelain¿ª·¢ÁËÒ»ÖÖÐÂÒªÁ죬£¬ £¬£¬£¬£¬Ê¹Óò¡¶¾ÔØÌå¶ÔÈËÀàTϸ°û¾ÙÐлùÒòÖØ×飬£¬ £¬£¬£¬£¬ÈÃTϸ°û±í´ï³öÌض¨µÄ¿¹ÔÊÜÌ壬£¬ £¬£¬£¬£¬´Ó¶ø°ÐÏò°©Ï¸°û¡£¡£ÕâЩÑо¿ÎªØʺóµÄCAR-Tϸ°ûÁÆ·¨µÓÚ¨ÁË»ù´¡¡£¡£
2012Ä꣬£¬ £¬£¬£¬£¬Carl JuneÍŶÓʹÓÃCAR-Tϸ°ûÁÆ·¨ÀÖ³ÉÖÎÓúÁËһλÃûΪEmilyµÄ¼±ÐÔ°×Ѫ²¡¸´·¢µÄСŮº¢¡£¡£2017Ä꣬£¬ £¬£¬£¬£¬FDAÅú×¼Á˵ÚÒ»¿îCAR-Tϸ°ûÁÆ·¨ÉÏÊУ¬£¬ £¬£¬£¬£¬ÏÖÔÚ£¬£¬ £¬£¬£¬£¬ÒÑÓÐ6¿îCAR-Tϸ°ûÁÆ·¨»ñµÃFDAÅú×¼ÉÏÊУ¬£¬ £¬£¬£¬£¬ÉÐÓÐÊý°ÙÏîÕýÔÚ¾ÙÐÐÁÙ´²ÊÔÑé¡£¡£
CAR-Tϸ°ûÁÆ·¨ÊÇÒ»ÖÖËùνµÄ¡°»îϸ°ûÒ©Î£¬£¬ £¬£¬£¬£¬ÊǰѲ¡È˵ÄTϸ°ûÔÚÌåÍâͨ¹ýÉúÎ﹤³ÌˢУ¬£¬ £¬£¬£¬£¬Ê¹Æäʶ±ðÖ×Áöϸ°ûÍâòµÄ¿¹Ô£¬£¬ £¬£¬£¬£¬È»ºó°ÑÕâЩϸ°ûÊä»Ø²¡ÈËÌåÄÚ£¬£¬ £¬£¬£¬£¬µÖ´ïʶ±ð¡¢É±ËÀ°©Ï¸°ûµÄЧ¹û¡£¡£CAR-Tϸ°ûÁÆ·¨µÄ·ºÆð¸Ä±äÁË°©Ö¢ÖÎÁÆÃûÌ㬣¬ £¬£¬£¬£¬ÔÚѪҺÖ×ÁöÖÐÕ¹ÏÖ³ö¹Å°åÁÆ·¨ÎÞ¿ÉÏà±ÈµÄÖÎÁÆЧ¹û¡£¡£
2023Äê11ÔÂ7ÈÕ£¬£¬ £¬£¬£¬£¬¼ÍÄî˹¡¿ÌØÁÕ°©Ö¢ÖÐÐĵÄMichel SadelainÍŶÓÔÚ°©Ö¢ÁìÓò¶¥¿¯ Cancer Discovery ÉϽÒÏþÁËÌâΪ¡°Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function ¡±µÄÑо¿ÂÛÎÄ¡£¡£
ÕâÏîÑо¿Åú×¢£¬£¬ £¬£¬£¬£¬Ö»ÐèÆÆËðCAR-Tϸ°ûÖеĵ¥¸ö»ùÒò¡ª¡ªSUV39H1£¬£¬ £¬£¬£¬£¬¾Í×ãÒÔÈÃCAR-Tϸ°û¸üÇ¿Ê¢£¬£¬ £¬£¬£¬£¬Ôö½øCAR-Tϸ°ûÀ©Ôö£¬£¬ £¬£¬£¬£¬±ÜÃâÆäºÄ½ß£¬£¬ £¬£¬£¬£¬×ÊÖúËüÃǸü³¤Ê±¼äµØ¶Ô¿¹Ö×Áö£¬£¬ £¬£¬£¬£¬±ÜÃâÖ×Áö¸´·¢¡£¡£ÕâÒ²ÌáÐÑÁËÎÒÃÇ£¬£¬ £¬£¬£¬£¬CAR-Tϸ°ûµÄ±í¹ÛÒÅ´«±à³Ì¾ßÓÐƽºâÆ书ЧºÍ³¤ÆÚÐÔµÄDZÁ¦£¬£¬ £¬£¬£¬£¬¿ÉÓÃÓÚ¸ÄÉƹý¼Ìϸ°ûÁÆ·¨¡£¡£
ÂÛÎÄÅäºÏµÚÒ»×÷ÕßNayan Jain²©Ê¿ÌåÏÖ£¬£¬ £¬£¬£¬£¬ÈôÊÇ¿ÉÒÔͨ¹ýÆÆË𵥸ö»ùÒòÀ´×ÊÖúCAR-Tϸ°ûά³ÖÆ书Ч£¬£¬ £¬£¬£¬£¬Õ⽫´øÀ´ÆÕ±éµÄÖÎÁÆÒæ´¦¡£¡£Ðí¶à°©Ö¢»¼ÕßÔÚ½ÓÊÜCAR-Tϸ°ûÖÎÁÆ֮ǰÒѾ½ÓÊÜÁ˶àÖÖ»¯ÁÆ£¬£¬ £¬£¬£¬£¬Õâµ¼ÖÂËûÃǵÄTϸ°û±»ºÄ¾¡£¡£¬£¬ £¬£¬£¬£¬Òò´ËÄÑÒÔÔöÖ³ºÍÓÐÓõضԿ¹°©Ö¢¡£¡£¶øÕâÏîÑо¿¿ª·¢µÄÐÂÒªÁìÖ»ÐèÒª¸üÉÙµÄCAR-Tϸ°û£¬£¬ £¬£¬£¬£¬¿ÉÒÔÀ©´óÇкÏÕâÖÖÖÎÁÆÌõ¼þµÄ°©Ö¢»¼ÕßȺÌ壬£¬ £¬£¬£¬£¬»¹»¹¿ÉÒÔÌá¸ß¶Ô»¼ÕßµÄÖÎÁÆЧ¹û¡£¡£
ÂÛÎÄÅäºÏµÚÒ»×÷ÕßÕÔÔó¹ú²©Ê¿ÌåÏÖ£¬£¬ £¬£¬£¬£¬Í¨¹ýÕâÖÖÐÂÒªÁ죬£¬ £¬£¬£¬£¬ÔÚÑÓÉìCAR-Tϸ°ûÊÙÃüµÄͬʱ£¬£¬ £¬£¬£¬£¬»¹Äܼá³ÖÆäÖ×ÁöɱÉËÄÜÁ¦£¬£¬ £¬£¬£¬£¬Òò´ËÎÒÃÇ¿ÉÒÔʹÓøüµÍµÄ¼ÁÁ¿À´ÖÎÁÆ»¼Õߣ¬£¬ £¬£¬£¬£¬Õâ¿ÉÄÜ»áïÔÌϸ°ûÒò×ÓÊÍ·Å×ÛºÏÕ÷£¨CRS£©µÄ·ºÆ𡣡£
ÔÚÖÎÁÆÀú³ÌÖУ¬£¬ £¬£¬£¬£¬CAR-Tϸ°û»áËæ×Åʱ¼äµÄÍÆÒƶøʧȥ¹¦Ð§£¬£¬ £¬£¬£¬£¬ÕâÖÖ±»³ÆΪTϸ°ûºÄ½ß£¨T cell exhaustion£©µÄÕ÷Ï󣬣¬ £¬£¬£¬£¬Ò»Ö±ÊÇCAR-Tϸ°ûÖÎÁÆÃæÁÙµÄÖ÷ÒªÕÏ°¡£¡£Õâ»áµ¼ÖÂCAR-Tϸ°ûÔÚ¶ÌÆÚÄÚÓÐÓᣡ£
30ÄêÇ°£¬£¬ £¬£¬£¬£¬Michel Sadelain ½ÌÊÚÊ×´ÎÉè¼ÆÁËTϸ°û£¬£¬ £¬£¬£¬£¬²¢Ò»Ö±ÖÂÁ¦ÓÚË¢ÐÂCAR-Tϸ°û¡£¡£ËûºÍÍŶӵÄÔçÆÚÑо¿Åú×¢£¬£¬ £¬£¬£¬£¬µ±Tϸ°ûÖеÄijЩ»ùÒò±»¹Ø±Õʱ£¬£¬ £¬£¬£¬£¬Tϸ°û»áËæ¼´±¬·¢ºÄ½ß£¬£¬ £¬£¬£¬£¬ÊÇʲô¹Ø±ÕÁËÕâЩ»ùÒò£¿£¿ÃÕµ×ÊÇ¡ª¡ªÏ¸°ûµÄ±í¹ÛÒÅ´«Ñ§¡£¡£
ÎÒÃÇ¿ÉÒ԰ѱí¹ÛÒÅ´«Ñ§±ÈÓ÷³ÉDNAÉϵĵ÷¹â¿ª¹Ø£¬£¬ £¬£¬£¬£¬µ÷¹â¿ª¹ØÔÚ²»¸Ä±äµÆ¾ßµÄÇéÐÎϸıäµÆ×Æ˸¶È¡£¡£Í¬ÑùµÄ£¬£¬ £¬£¬£¬£¬±í¹ÛÒÅ´«Ñ§¿ÉÒÔÔÚ²»¸Ä±äDNAÐòÁеÄÇéÐÎÏ£¬£¬ £¬£¬£¬£¬¸Ä±ä»ùÒò±í´ïˮƽ¡£¡£
Ðí¶à±í¹ÛÒÅ´«Ñ§×ª±äµÄ±¬·¢ÊÇÓÉÓÚDNAÔÚϸ°ûºËÖеİü×°·½·¨¡£¡£ÔÚȾɫÌåÖУ¬£¬ £¬£¬£¬£¬DNAË«Á´±»³ÆΪ×éÂÑ°×µÄÂÑ°×ÖÊ°ü¹ü×Å£¬£¬ £¬£¬£¬£¬ÔÚDNAºÍÂÑ°×ÖÊϸÃÜ°ü×°µÄÇøÓò£¬£¬ £¬£¬£¬£¬»ùÒòÊDz»¿É»á¼ûµÄ£¬£¬ £¬£¬£¬£¬Ò²ÎÞ·¨Æô¶¯±í´ï¡£¡£
SUV39H1ÊÇÒ»ÖÖH3K9¼×»ùתÒÆø£¬£¬ £¬£¬£¬£¬½éµ¼H3K9¼×»ù»¯£¬£¬ £¬£¬£¬£¬´Ó¶øÒÖÖƶà¸ö»ùÒòµÄ±í´ï¡£¡£Ñо¿ÍŶÓÒÔΪ£¬£¬ £¬£¬£¬£¬ÓëÆäÊÔͼ¸Ä±äËùÓÐÕâЩ±»ÒÖÖƵĻùÒòµÄ±í´ï£¬£¬ £¬£¬£¬£¬²»ÈçרעÓÚÆÆËðSUV39H1£¬£¬ £¬£¬£¬£¬´Ó¶øͬʱ΢µ÷±»ÆäÒÖÖƵĶà¸ö»ùÒòµÄ±í´ï£¬£¬ £¬£¬£¬£¬ÒÔÔöÇ¿Tϸ°û¹¦Ð§¡£¡£
Ñо¿ÍŶÓʹÓÃCRISPR-Cas9»ùÒò±à¼ÊÖÒÕÇóýÁËÈËÀàCAR-Tϸ°ûÖеÄSUV39H1»ùÒò£¬£¬ £¬£¬£¬£¬È»ºó½«ÕâЩ»ùÒò±à¼¹ýµÄCAR-Tϸ°ûÊäÈëÒÆÖ²ÁËÈËÀà°×Ѫ²¡Ï¸°û»òÇ°ÏßÏÙ°©Ï¸°ûµÄСÊóÌåÄÚ¡£¡£Ð§¹ûÏÔʾ£¬£¬ £¬£¬£¬£¬¹ØÓÚÕâÁ½ÖÖ°©Ö¢£¬£¬ £¬£¬£¬£¬»ùÒò±à¼¹ýµÄCAR-Tϸ°ûÄܹ»Î¬³ÖËüÃǵĹ¦Ð§¶ø²»»áºÄ½ß£¬£¬ £¬£¬£¬£¬´Ó¶øµ¼ÖÂÖ×ÁöµÄÍêÈ«Ïû³ý¡£¡£Ïà±È֮ϣ¬£¬ £¬£¬£¬£¬Î´¾»ùÒò±à¼µÄCAR-Tϸ°ûÖÎÁƵÄÖ×ÁöСÊóÄ£×ÓδÄÜ´æ»î¡£¡£
±ðµÄ£¬£¬ £¬£¬£¬£¬ÎªÁËÑéÖ¤»ùÒò±à¼¹ýµÄCAR-Tϸ°ûµÄ³¤ÆÚÐÔ£¬£¬ £¬£¬£¬£¬Ñо¿ÍŶӽ«ÖÎÁƺóµÄСÊó̻¶ÓÚеÄÖ×Áö£¬£¬ £¬£¬£¬£¬Ð§¹ûÏÔʾ£¬£¬ £¬£¬£¬£¬ÇóýSUV39H1»ùÒòµÄCAR-Tϸ°ûÄܹ»±ÜÃâÖ×Áö¸´·¢¡£¡£
ÕâÏîÔÚСÊóÄ£×ÓÉϾÙÐеÄÁÙ´²Ç°Ñо¿Ö¤ÊµÎúÇóýSUV39H1»ùÒòµÄCAR-Tϸ°û²»µ«¾ßÓиüÇ¿¡¢¸ü³¤ÆڵĿ¹Ö×ÁöЧ¹û£¬£¬ £¬£¬£¬£¬²¢ÇÒδ·¢Ã÷ÑÏÖظ±×÷Óᣡ£±ðµÄ£¬£¬ £¬£¬£¬£¬Ñо¿ÍŶÓÒѽ«¸ÃÊÖÒÕÊÚȨ¸øÁËÉúÎïÊÖÒÕ¹«Ë¾Mnemo Therapeutics£¬£¬ £¬£¬£¬£¬ÒÔÍƽø»ùÓÚÕâÏîÑо¿µÄÁÙ´²ÊÔÑé¡£¡£
